ReviewRSC advances2026
Carrier-free self-assembled nanomedicines from natural small molecules: advances and perspectives for disease treatment.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Investigation of the Potential Neuroprotective Mechanisms ofInternational journal of molecular sciences · 2026Article
- Nanomedicine in 2026: Illustrative Quantitative Analyses of EPR Heterogeneity, Clinical Trial Attrition, and Emerging Horizons for Active Nanotherapeutics.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carrier-free self-assembled nanomedicines (CFSNs) derived from natural small molecules (NSMs) have garnered significant attention in the field of nanomedicine due to their unique properties and potential therapeutic applications. This review provides an in-depth analysis of the recent advances in the development and application of CFSNs for disease treatment. We discuss the self-assembly mechanisms of NSMs, such as polyphenols, alkaloid, and terpenoid, which form stable and biocompatible nanoscale structures without the need for synthetic carriers. The fundamental forces driving self-assembly, including hydrogen bonding, π-π stacking interactions, electrostatic interactions, and coordination interactions, are elucidated in the first section. These CFSNs exhibit enhanced solubility, improved pharmacokinetics, and reduced toxicity compared to their bulk counterparts. The therapeutic potential of CFSNs is evaluated across various disease models, including cancer, infection, inflammation, cardiovascular diseases, and neurodegenerative disorders. We also address the challenges associated with the clinical translation of CFSNs, such as scalability, reproducibility, and regulatory approval. Finally, we offer perspectives on future research directions, emphasizing the need for interdisciplinary collaboration to fully harness the therapeutic potential of CFSNs. This comprehensive overview aims to provide a foundation for further exploration and development of CFSNs as a promising platform for next-generation nanotherapeutics.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.